Quality of Life in Melasma

  • Andreas KatsambasEmail author
  • Efthymia Soura


  • Melasma is an acquired disorder of hyperpigmentation that affects millions of people worldwide. Severity is affected by seasonal changes. Long-term treatments needed for the condition are costly yet may prove only moderate results. As a result, melasma may be distressing for patients.

  • During the last few years, a number of quality of life measures have been used in order to assess the way that melasma influences patient’s everyday life. These include both disease-specific instruments, such as the Melasma Quality of Life (MELASQoL) scale, and non-disease-specific instruments, such as the Dermatology Life Quality Index (DLQI) and Skindex questionnaires.

  • Results from various studies were concordant in the fact that melasma is associated with decreased quality of life and that it exerts influence on specific aspects of everyday living.

  • Interestingly, the effects of melasma in quality of life may not reflect the actual severity of the condition. Given the fact that melasma lacks physical symptoms such as pruritus, pain, or scaling, it is important to assess the emotional burden associated with its presence.

  • Understanding the psychosocial concerns of patients may lead to improved compliance, based on realistic expectations and on treatment affordability. In addition, assessing patient quality of life during and after treatment may also be used as an indication for treatment efficacy.


Melasma QoL DLQI MELASQoL Skindex 


  1. 1.
    Nicolaidou E, Katsambas AD. Pigmentation disorders: hyperpigmentation and hypopigmentation. Clin Dermatol. 2014;32(1):66–72.CrossRefPubMedGoogle Scholar
  2. 2.
    Stratigos AJ, Katsambas AD. Optimal management of recalcitrant disorders of hyperpigmentation in dark-skinned patients. Am J Clin Dermatol. 2004;5(3):161–8.CrossRefPubMedGoogle Scholar
  3. 3.
    McHorney CA. Health status assessment methods for adults: past accomplishments and future challenges. Annu Rev Public Health. 1999;20:309–35.CrossRefPubMedGoogle Scholar
  4. 4.
    Augustin M, Langenbruch AK, Gutknecht M, Radtke MA, Blome C. Quality of life measures for dermatology: definition, evaluation, and interpretation. Curr Derm Rep. 2012;1(3):148–59.CrossRefGoogle Scholar
  5. 5.
    Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107(5):707–13.CrossRefPubMedGoogle Scholar
  7. 7.
    Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433–40.CrossRefPubMedGoogle Scholar
  8. 8.
    Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5(2):105–10.CrossRefPubMedGoogle Scholar
  9. 9.
    Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;149(3):572–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Pandya A, Berneburg M, Ortonne JP, Picardo M. Guidelines for clinical trials in melasma. Pigmentation Disorders Academy. Br J Dermatol. 2006;156 Suppl 1:21–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Taylor SC, Torok H, Jones T, Lowe N, Rich P, Tschen E, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72(1):67–72.PubMedGoogle Scholar
  12. 12.
    Kimbrough-Green CK, Griffiths CE, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, Ellis CN, Voorhees JJ. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch Dermatol. 1994;130(6):727–33.CrossRefPubMedGoogle Scholar
  13. 13.
    Dominguez AR, Balkrishnan R, Ellzey AR, Pandya AG. Melasma in Latina patients: cross-cultural adaptation and validation of a quality-of-life questionnaire in Spanish language. J Am Acad Dermatol. 2006;55(1):59–66.CrossRefPubMedGoogle Scholar
  14. 14.
    Dogramaci AC, Havlucu DY, Inandi T, Balkrishnan R. Validation of a melasma quality of life questionnaire for the Turkish language: the MelasQoL-TR study. J Dermatol Treat. 2009;20(2):95–9.CrossRefGoogle Scholar
  15. 15.
    Ikino JK, Nunes DH, da Silva VPM, Frode TS, Sens MM. Melasma and assessment of the quality of life in Brazilian women. An Bras Dermatol. 2015;90(2):196–200.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Freitag FM, Cestari TF, Leopoldo LR, Paludo P, Boza JC. Effect of melasma on quality of life in a sample of women living in southern Brazil. J Eur Acad Dermatol Venereol. 2008;22(6):655–62.CrossRefPubMedGoogle Scholar
  17. 17.
    Tamega AA, Miot LDB, Bonfietti C, Gige TC, Marques MEA, Miot HA. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. J Eur Acad Dermatol Venereol. 2013;27(2):151–6.CrossRefGoogle Scholar
  18. 18.
    Purim KS, Avelar MF. [Photoprotection, melasma and quality of life in pregnant women]. Rev Bras Ginecol Obstet: Revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia. 2012;34(5):228–34.Google Scholar
  19. 19.
    Handel AC, Miot LDB, Miot HA. Melasma: a clinical and epidemiological review. An Bras Dermatol. 2014;89(5):771–82.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Cestari TF, Hexsel D, Viegas ML, Azulay L, Hassun K, Almeida ART, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. Br J Dermatol. 2006;156(S1):13–20.CrossRefPubMedGoogle Scholar
  21. 21.
    Ali R, Aman S, Nadeem M. Quality of life in patients of melasma. J Pak Assoc Dermatol. 2013;23(2):143–8.Google Scholar
  22. 22.
    Leeyaphan C, Wanitphakdeedecha R, Manuskiatti W, Kulthanan K. Measuring melasma patients’ quality of life using willingness to pay and time trade-off methods in Thai population. BMC Dermatol. 2011;11:16.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Pichardo R, Vallejos Q, Feldman SR, Schulz MR, Verma A, Quandt SA, Arcury TA. The prevalence of melasma and its association with quality of life in adult male Latino migrant workers. Int J Dermatol. 2009;48(1):22–6.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer India 2017

Authors and Affiliations

  1. 1.1st University Clinic of Dermatology and VenereologyAndreas Sygros Hospital, University of AthensAthensGreece

Personalised recommendations